---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-055203"
form_type: "8-K"
ticker: "IDXX"
cik: "0000874716"
company_name: "IDEXX LABORATORIES INC /DE"
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:41:53.713612+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# IDEXX Q1 beats: rev $1.14B (+14%), EPS $3.47 (+17%); raises FY guidance

## Summary
- Q1 revenue $1,141M (+14% as reported, +11% organic); EPS $3.47 (+17% as reported, +15% comparable).
- CAG Diagnostics recurring revenue +14% as reported, +11% organic; premium instrument installed base +12%.
- FY2026 revenue guidance raised $42M at midpoint to $4,675-$4,760M; EPS guidance to $14.45-$14.90.
- Organic revenue growth guidance raised to 7.7%-9.7% from 7.0%-9.0%; operating margin expansion 50-90 bps.
- CEO Jay Mazelsky to transition; Mike Erickson will continue as a key leader (mentioned in earnings release).

## SEC filing metadata
- accession: 0001104659-26-055203
- form_type: 8-K
- ticker: IDXX
- cik: 0000874716
- company_name: IDEXX LABORATORIES INC /DE
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874716/000110465926055203/0001104659-26-055203-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874716/000110465926055203/tm2613510d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-055203
- JSON: https://secwatch.observer/filing/0001104659-26-055203.json
- Plain text: https://secwatch.observer/filing/0001104659-26-055203.txt

## Key facts
- Earnings Releases
  IDEXX LABORATORIES INC /DE reported the quarter ended March 31, 2026 results: revenue $1,141 million, EPS $3.47. Guidance raised.
  - Period: the quarter ended March 31, 2026
  - Revenue: $1,141 million
  - EPS: $3.47
  - Guidance: raised
  - Result: reported results
  source text: Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. First Quarter Results The Company reports revenues of $1,141 million for the first quarter of 2026, an increase of 14% as reported and 11% organic, driven by Companion Animal Group ("CAG") growth of 15% as reported and 12% organic. First quarter
  evidence_url: https://www.sec.gov/Archives/edgar/data/874716/000110465926055203/0001104659-26-055203-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.